Taiwan Bio Therapeutics Co., Ltd

Equities

6892

TW0006892003

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-06-11 pm EDT			5-day change	1st Jan Change
38 ^TWD	-0.52%		-0.52%	+10.79%

Mar. 12	TRACT Therapeutics and Taiwan Bio Therapeutics Announce to Launch Phase 2 Clinical Trial Investigating Ability of Treg Therapy to Reduce Use of Immunosuppressant Drugs in Living Donor Kidney Transplant Recipients	CI
2023	Taiwan Bio and TRACT Therapeutics, Inc. Announce Strategic Partnership to Advance a Novel Therapeutic Approach for Preventing Rejection in Solid Organ Transplant	CI

TRACT Therapeutics and Taiwan Bio Therapeutics Announce to Launch Phase 2 Clinical Trial Investigating Ability of Treg Therapy to Reduce Use of Immunosuppressant Drugs in Living Donor Kidney Transplant Recipients

March 12, 2024 at 06:00 am EDT

TRACT Therapeutics and Taiwan Bio Therapeutics announced to launch a Phase 2 clinical trial investigating the ability of Treg therapy to reduce the use of immunosuppressant drugs in living donor kidney transplant recipients. Research centers will be located in the United States and Taiwan.

Latest news about Taiwan Bio Therapeutics Co., Ltd

TRACT Therapeutics and Taiwan Bio Therapeutics Announce to Launch Phase 2 Clinical Trial Investigating Ability of Treg Therapy to Reduce Use of Immunosuppressant Drugs in Living Donor Kidney Transplant Recipients	Mar. 12	CI
Taiwan Bio and TRACT Therapeutics, Inc. Announce Strategic Partnership to Advance a Novel Therapeutic Approach for Preventing Rejection in Solid Organ Transplant	Dec. 06	CI

Chart Taiwan Bio Therapeutics Co., Ltd

Duration

Period

More charts

Company Profile

Taiwan Bio Therapeutics Co Ltd is a Taiwan-based company mainly engaged in the development of new allogeneic stem cell drugs and the provision of contract development and manufacturing organization (CDMO) services. The main products include Chondrochymal for the treatment of degenerative arthritis of the knee, Biochymal for the treatment of difficult non-healing wounds caused by lower extremity ischemia, OmniMSC/TBPCB201 for the treatment of acute myocardial infarction, and MSC-VEGF for the treatment of lower extremity ischemia. The cell processing center (CPC) is engaged in the provision of a full set of CDMO services, process scale-up services, inspection and development services, and quality control commissioned inspection services. The Company mainly operates in Taiwan market.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TAIWAN BIO THERAPEUTICS CO., LTD	+10.79%	59.89M
MODERNA, INC.	+47.54%	56.61B
IQVIA HOLDINGS INC.	-7.58%	39.62B
LONZA GROUP AG	+35.71%	39.25B
CELLTRION, INC.	-6.90%	28.28B
ICON PUBLIC LIMITED COMPANY	+10.68%	26.44B
ALNYLAM PHARMACEUTICALS, INC.	-16.60%	20.12B
UNITED THERAPEUTICS CORPORATION	+29.52%	12.51B
MEDPACE HOLDINGS, INC.	+30.23%	12.48B
BIO-TECHNE CORPORATION	-0.34%	12.2B

Other Biotechnology & Medical Research